WHO: Chapeau! [BE/BA News]

posted by nobody – 2017-06-13 11:28 (2449 d 07:19 ago) – Posting: # 17492
Views: 9,535

❝ It of course comes at a handy time when WHO are opening up for biologics. This isn't a co-incidence :-D:-D:-D.


Didn't have a look at PARs, but EMA has a high number of biosimilars approved (compared to e.g. FDA), is the variability in AUC really an issue and how did the applicants account for, if EMA allows no scaling for AUC?

Just asking... :-)

Kindest regards, nobody

Complete thread:

UA Flag
 Admin contact
22,912 posts in 4,806 threads, 1,635 registered users;
35 visitors (0 registered, 35 guests [including 10 identified bots]).
Forum time: 17:48 CET (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz